Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia | Zendy

Ariel GraffGuerrero | Zendy; Tarek K. Rajji | Zendy; Benoit H. Mulsant | Zendy; Shinichiro Nakajima | Zendy; Fernando Caravaggio | Zendy; Takefumi Suzuki | Zendy; Hiroyuki Uchida | Zendy; Philip Gerretsen | Zendy; Wanna Mar | Zendy; Bruce G. Pollock | Zendy; David C. Mamo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia

Author(s) -

Ariel GraffGuerrero,

Tarek K. Rajji,

Benoit H. Mulsant,

Shinichiro Nakajima,

Fernando Caravaggio,

Takefumi Suzuki,

Hiroyuki Uchida,

Philip Gerretsen,

Wanna Mar,

Bruce G. Pollock,

David C. Mamo

Publication year - 2015

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2015.0891

Subject(s) - antipsychotic , risperidone , medicine , olanzapine , akathisia , brief psychiatric rating scale , schizophrenia (object oriented programming) , positive and negative syndrome scale , adverse effect , psychiatry , psychology , psychosis

Patients with late-life schizophrenia (LLS) are highly susceptible to antipsychotic adverse effects. Treatment guidelines endorse lower antipsychotic doses. However, the optimal dose of antipsychotics and associated dopamine D2/3 receptor (D2/3R) occupancies remain largely unexplored in patients with LLS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research